InvestorsHub Logo
Followers 63
Posts 24430
Boards Moderated 0
Alias Born 11/23/2016

Re: Steady_T post# 173449

Saturday, 12/01/2018 1:54:21 PM

Saturday, December 01, 2018 1:54:21 PM

Post# of 470066
Tred’s post wording in regards to biomarkers seems ok to me.

The biomarkers are as you say specific to how efficacious A2-73 is, although it seems only by a small margin, depending on the wild type vs. specific variants of the COMT and SIGMAR1 genes regardless of indication.

I think the genetic biomarkers will help in validating A2-73 as having predictable features and possibly provide further insight to neurological disease pathways, which can’t be bad for regulatory approval. How clinical meaningful those biomarkers are remains to be seen.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News